LCOV
TEVA icon

London Company of Virginia’s Teva Pharmaceuticals TEVA Stock Holding History

London Company of Virginia’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,693
Closed -$230K – 152
2015
Q1 		$230K Buy
+3,693
New +$215K ﹤0.01% 132

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

London Company of Virginia's TEVA Position: Q2 2015 in Review

London Company of Virginia sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 3,693 shares — an estimated $230K sold.

London Company of Virginia first reported a position in TEVA in Q1 2015 and held it in 1 quarter. The position peaked at $230K in Q1 2015. 819 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

  • London Company of Virginia reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • London Company of Virginia sold 3,693 Teva Pharmaceuticals shares in Q2 2015, an estimated $230K.
  • London Company of Virginia first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • London Company of Virginia's Teva Pharmaceuticals position peaked at $230K in Q1 2015.
  • 819 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on London Company of Virginia's 13F filing for Q2 2015, filed 14 Aug 2015.